Atlas Trials

IGM Biosciences, Inc.

10 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch IGM Biosciences, Inc.

RecordFirmDate
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies (NCT06524687)IGM Biosciences, Inc.2024-05-29
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma (NCT05908396)IGM Biosciences, Inc.2023-08-29
A Study of Imvotamab in Severe Systemic Lupus Erythematosus (NCT06041568)IGM Biosciences, Inc.2023-08-15
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis (NCT06087406)IGM Biosciences, Inc.2023-03-15
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer (NCT05702424)IGM Biosciences, Inc.2023-01-10
Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19 (NCT05184218)IGM Biosciences, Inc.2022-01-20
Evaluation of IGM-6268 in Healthy Volunteers (NCT05160402)IGM Biosciences, Inc.2021-12-07
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers (NCT04553692)IGM Biosciences, Inc.2020-09-23
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (NCT04082936)IGM Biosciences, Inc.2019-09-30

Track IGM Biosciences, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.